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Increased uranium levels in groundwater are
associated with uranium-rich ores and high sol-
ubility of uranium under oxidizing conditions
in soft and bicarbonate-rich waters (Salonen
1994). Consequently, exceptionally high ura-
nium concentrations have been found in pri-
vate drilled wells located mostly in the southern
part of Finland (Salonen and Huikuri 2002).
We identiﬁed earlier a cohort of people who
live in that area and use drilled wells for drink-
ing water (Kurttio et al. 2002).
In long-term exposure, uranium accumu-
lates in the bone and kidneys (Leggett and
Pellmar 2003; Pellmar et al. 1999). The kid-
ney has been considered the main target
organ of chemical toxicity of uranium in
humans, but effects in other tissues or organs
remain poorly known. The intake of natural
uranium through drinking water is associated
with kidney function, particularly increased
fractional excretion of calcium and phosphate
in urine (Kurttio et al. 2002). The implica-
tions of the accumulation of natural uranium
in the bone in humans are not known. The
early distribution of uranium in the skeleton is
similar to that of calcium (Leggett 1994).
Uranium is assumed to deposit on the bone
surface, and the uranyl ion (UO2
2+) is assumed
to be exchanged with calcium ions at the 
surfaces of bone mineral crystals but not to
participate in crystal formation (Leggett 1994).
Gradually, uranium is redistributed in the
bone and other tissues. The current biokinetic
model of the International Commission on
Radiological Protection suggests three com-
partments for uranium in human bone: bone
surface, exchangeable bone volume, and
nonexchangeable bone volume (Leggett 1994).
It also suggests that uranium leaves bone sur-
faces more slowly than does calcium and that
the removal from the nonexchangeable bone
compartment may occur but with the rate of
bone turnover.
The resemblance of uranium metabolism
to that of calcium in bone enables the effects of
uranium on bone. Indeed, uranium adminis-
tration in rats is known to affect the bone.
Acute (Guglielmotti et al. 1984) or continuous
(Diaz Sylvester et al. 2002) exposure to ura-
nium may lead to decreased bone formation
rate and also increased bone resorption (Ubios
et al. 1991) in rats.
The aim of this study was to assess whether
uranium intake through drinking water affects
the biochemical markers of bone turnover in
humans. The present study extends our previ-
ous study, which suggested that uranium expo-
sure is associated with altered proximal renal
tubular function (Kurttio et al. 2002). To our
knowledge, this is the ﬁrst report on the possi-
ble effects of ingested natural uranium on bone
in humans.
Materials and Methods
Study population. The source population was
identified from the drinking water database
of STUK–Radiation and Nuclear Safety
Authority, with radionuclide analyses of more
than 5,000 drilled wells. This study was lim-
ited to southern Finland, where uranium con-
centrations are highest. The study population
was a subpopulation of our previous study on
effects of natural uranium on kidney function,
with a more detailed description published ear-
lier (Kurttio et al. 2002). The ﬁrst question-
naire was mailed to 798 households. Based
on the first questionnaire, 436 persons were
selected, with a maximum of two persons per
household where a drilled well had been used
for drinking water at least for the previous year
(median duration of use, 11 years). The second
questionnaire was used to collect information
on residential history and use of drilled well
water and its daily consumption, use of other
beverages, smoking history, education, occupa-
tion, disease history, and use of medication and
herbal products. Seventy-eight percent of the
persons who received the second questionnaire
agreed to participate in the study (samples were
received from these persons). Further informa-
tion on, for example, bone fracture history and
information on menopause and on physical
activity was also collected (67% replied to this
third questionnaire). We do not have informa-
tion on type or date of the bone fractures.
Subjects were excluded if they were
< 25 years of age (n = 11); had diabetes mellitus
(n = 4); reported long-term use of gluco-
corticoids (n = 11), thiazide diuretics (n = 7),
methotrexate (n = 1), or sodium aurothiomalate
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Uranium accumulates in bone, affects bone metabolism in laboratory animals, and when ingested
in drinking water increases urinary excretion of calcium and phosphate, important components in
the bone structure. However, little is known about bone effects of ingested natural uranium in
humans. We studied 146 men and 142 women 26–83 years of age who for an average of 13 years
had used drinking water originating from wells drilled in bedrock, in areas with naturally high
uranium content. Biochemical indicators of bone formation were serum osteocalcin and amino-
terminal propeptide of type I procollagen, and a marker for bone resorption was serum type I collagen
carboxy-terminal telopeptide (CTx). The primary measure of uranium exposure was uranium con-
centration in drinking water, with additional information on uranium intake and uranium concen-
tration in urine. The data were analyzed separately for men and women with robust regression
(which suppresses contributions of potential inﬂuential observations) models with adjustment for
age, smoking, and estrogen use. The median uranium concentration in drinking water was 27 µg/L
(interquartile range, 6–116 µg/L). The median of daily uranium intake was 36 µg (7–207 µg) and of
cumulative intake 0.12 g (0.02–0.66 g). There was some suggestion that elevation of CTx (p = 0.05)
as well as osteocalcin (p = 0.19) could be associated with increased uranium exposure (uranium in
water and intakes) in men, but no similar relationship was found in women. Accordingly, bone may
be a target of chemical toxicity of uranium in humans, and more detailed evaluation of bone effects
of natural uranium is warranted. Key words: bone, bone turnover markers, CTx, drinking water,
osteocalcin, P1NP, uranium. Environ Health Perspect 113:68–72 (2005). doi:10.1289/ehp.7475
available via http://dx.doi.org/ [Online 30 September 2004](n = 1); were currently pregnant (n = 4); or
used effective equipment for removing ura-
nium from well water (n = 4). The ﬁnal study
population consisted of 288 persons from
179 households. Most of the study persons had
never smoked, and their average body mass
index was 25 kg/m2 (Tables 1 and 2). Twenty-
six women used estrogen (oral contraceptives
or hormonal replacement therapy) regularly
during the previous year, and the women had
had two deliveries on average. None of the
subjects reported hyperparathyroidism.
The study protocol was approved by the
National Public Health Institute Standing
Committee on Ethics (project 8/030399).
Sample collection and preparation. The
water, urine, and nonfasting blood samples
were collected between 14 September and
1 December 1999. The samples were collected
at a time when the study persons had con-
sumed water from the drilled well throughout
the previous week. Samples were not taken
unless at least 1 week had elapsed since an acute
infection. The study persons brought the water
and urine samples collected overnight to the
laboratory in the morning. At the same visit,
blood samples were taken (77% of the samples
were taken before 1100 hr). In addition, body
weight and height were measured in a standard-
ized fashion. The water and overnight urine
samples for uranium analyses were conserved
with concentrated HNO3. Water samples were
stored at room temperature but serum and
urine samples frozen at –20oC until analyzed.
Uranium exposure assessment. Uranium in
drinking water and urine were analyzed blind
with inductively coupled plasma mass spec-
trometry. The analysis and quality control pro-
cedure are described by Kurttio et al. (2002).
The primary measure of uranium exposure
was uranium concentration in drinking water
(micrograms per liter). In addition, we meas-
ured daily intake of uranium from drinking
water (volume used × concentration, micro-
grams), cumulative intake from drinking
water (daily intake × duration of the water
consumption, grams), and uranium con-
centration in urine (micrograms per liter or
micrograms per millimole creatinine). The
exposure variables were highly correlated with
each other (Table 3).
Outcome variables. Serum osteocalcin and
amino-terminal propeptide of type I procolla-
gen (P1NP) were used as indicators of bone
formation, reﬂecting different stages of osteo-
blast differentiation. We analyzed osteocalcin
using an immunoradiometric assay, which
measures human osteocalcin (1-49) and human
osteocalcin peptide (1-43) (ELSA-OSTEO;
CIS Bio International, Gif-sur-Yvette, France).
At the 15-µg/L level, the intra- and interassay
variations were 2.0 and 3.1%, respectively.
P1NP was analyzed with a commercial radio-
immunoassay (Procollagen Intact P1NP; Orion
Diagnostica, Oulunsalo, Finland); intra- and
interassay variations at the 40-µg/L level were
2.0 and 4.9%, respectively.
Serum type I collagen carboxy-terminal
telopeptide (CTx) was used as an indicator of
bone resorption. CTx was analyzed with an
enzyme immunoassay (Serum CrossLaps One
Step ELISA; Osteometer Biotech, Herlev,
Denmark); intra- and interassay variations at
the 2.4-nmol/L level were 6.4 and 7.2%,
respectively.
In men, the correlation between the log-
transformed osteocalcin and P1NP was 0.70;
between osteocalcin and CTx, 0.38; and
between P1NP and CTx, 0.32. In women,
the correlations were 0.63, 0.46, and 0.36,
respectively.
Urine calcium was measured with atomic
absorption spectrophotometry (EFOX 5053;
Eppendorf, Hamburg, Germany) (detection
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Table 1. Description of age and smoking by sex in
the study population.
Men Women
[no. (%)] [no. (%)]
Age (years)
< 45 42 (29) 46 (32)
45–55 34 (23) 40 (28)
55–65 50 (34) 30 (21)
≥ 65 20 (14) 26 (18)
Smoking
Never 69 (47) 94 (66)
Ex 53 (36) 31 (22)
Current 18 (12) 14 (10)
Missing 6 (4) 3 (2)
Total 146 (100) 142 (100)
Table 2. Basic information on the study population, uranium exposure, and levels of indicators of bone turnover and urinary calcium, phosphate, and creatinine.
Percentile
Characteristic No. Mean Median 25th 75th Minimum Maximum
Men
Age (years) 146 53 54 44 61 26 78
Body mass index (kg/m2) 143 26 25 24 28 20 35
Duration of the use of drilled well (years) 146 13 11 6 20 2 34
Uranium in drinking water (µg/L) 146 124 28 6 122 0.087 1,920
Daily intake of uranium from drinking water (µg) 146 216 36 8 207 0.2 4,128
Cumulative intake of uranium from drinking water (g) 146 1.33 0.12 0.02 0.60 0.001 33
Uranium in urine (µg/L) 146 0.29 0.06 0.01 0.27 0.001 4.54
Uranium in urine (µg/mmol creatinine) 146 0.041 0.007 0.002 0.032 0.0001 0.333
Urine calcium (mmol/hr) 146 0.7 0.3 0.1 0.6 0.04 19
Urine phosphate (mmol/hr) 146 3.9 2.6 1.3 4.6 0.3 19
Urine creatinine (mmol/L) 146 8.5 7.8 5.4 10.4 1.2 28
Serum osteocalcin (µg/L) 146 21 20 16 25 7 54
Serum P1NP (µg/L) 146 42 37 31 48 15 178
Serum CTx (nmol/L) 146 3.4 2.4 1.7 3.3 0.4 65
Women
Age (years) 142 52 53 43 61 28 83
Body mass index (kg/m2) 128 25 24 22 26 18 41
No. of deliveries 82 2 2 2 3 0 6
Duration of the use of drilled well (years) 142 13 11 6 19 1 34
Uranium in drinking water (µg/L) 142 113 26 5 115 0.001 930
Daily intake of uranium from drinking water (µg) 142 212 36 7 207 0.0 2,748
Cumulative intake of uranium from drinking water (g) 142 1.21 0.12 0.03 0.73 0.000 30
Uranium in urine (µg/L) 142 0.38 0.09 0.02 0.42 0.001 3.25
Uranium in urine (µg/mmol creatinine) 142 0.075 0.019 0.004 0.087 0.0003 0.571
Urine calcium (mmol/hr) 141 0.4 0.2 0.1 0.5 0.03 3.0
Urine phosphate (mmol/hr) 141 3.0 1.7 1.0 3.3 0.1 17
Urine creatinine (mmol/L) 142 6.3 5.4 3.7 7.8 0.9 24
Serum osteocalcin (µg/L) 142 21 19 15 24 6 121
Serum P1NP (µg/L) 142 38 34 26 47 9 152
Serum CTx (nmol/L) 142 2.8 2.3 1.5 3.3 0.4 40limit, 0.1 mmol/L). Urine phosphate was
measured based on a colored complex with
ammonium molybdate (Konelab 60I; Konelab
Co., Espoo, Finland) (detection limit,
2.0 mmol/L). Urinary excretions of calcium
and phosphate (millimoles per hour) were cal-
culated from the volume of urine divided by
the overnight collection time. The mean ± SD
excretion of urine was 79 ± 36 mL/hr in men
and 78 ± 37 mL/hr in women.
Statistics. For all the parameters deter-
mined, the observations below the detection
limits were recorded as half of the detection
limit. An analysis of the residuals indicated
that they were not normally distributed and
that some of the observations were highly
influential. Therefore, the robust regression
method using iteratively reweighted least
squares (Huber and Tukey bi-square weight
function) with rreg routine in Stata/SE 8.1 for
Windows (Stata Corp., College Station, TX,
USA) was used. Robust regression assigns a
weight to each observation, with lower weights
given to possible influential observations.
Some results from the conventional linear
regression are also given in “Results.”
The analyses were performed separately for
men and women. For men, markers of bone
metabolism levels were modeled using linear
and quadratic terms for age and a variable for
current smoking. The model used for women
included a categorical age term [< 45 (refer-
ence), 45–55, 55–65, and ≥ 65 years], with
additional variables for recent regular estrogen
use and current smoking.
Algebraically these are as follows:
ln(y) = α + b1 ln(x) + b2 age 
+ b3 age2 + b4 smo (for men)
and ln(y) = α + b5 ln(x) + b6 agecat
+ b7 smo + b8 estro (for women),
in which y is the indicator of bone metabo-
lism, α is a constant, b is the regression coefﬁ-
cient, x is continuous uranium exposure,
agecat is age category (45–55, 55–65, and
≥ 65 years), smo is current smoking status,
and estro is use of estrogens, the last two
being binary indicator (dummy) variables. R2
and p-values of the models are described in
Table 4.
Analyses were also carried out using the
above-mentioned models with log-trans-
formed urinary calcium or phosphate excre-
tions as explanatory variables.
Results
Background. For men, the levels of osteocalcin,
P1NP, and CTx tended to decrease with age
until about 60 years of age, after which bone
turnover appeared to increase gradually but
age accounts for a relatively small proportion of
the variation in the bone turnover measure-
ments (Figure 1). All p-values were < 0.01 for
associations between the linear age variable
and all outcome variables. In men, current
smoking was associated with decreased levels
of osteocalcin (p = 0.01), P1NP (p = 0.11),
and CTx (p = 0.03).
For women, the levels of osteocalcin,
P1NP, and CTx were highest in the age group
of 55–65 years, but the differences between the
age groups were not statistically significant
(Figure 1). Smoking in women was not statisti-
cally signiﬁcantly associated with any marker of
bone turnover. Estrogen use was associated
with significantly decreased levels of osteo-
calcin, P1NP, and CTx (Figure 1).
Uranium exposure. The uranium con-
centration in water varied from 0.001 to
1,920 µg/L (Table 2), with 27% of the con-
centrations > 100 µg/L and 59% > 15 µg/L.
The median daily intake of uranium from
drinking water was 36 µg, and the cumula-
tive intake was 120 mg. The median annual
committed equivalent radiation dose of bone
surfaces was 0.36 mSv/year (maximum,
41 mSv/year), based on the uranium intake
and the average uranium isotope activity
ratios measured in Finnish drilled well waters
(234U:238U = 2) and dose conversion factors
(234U, 7.4 × 10–7 Sv/Bq; 238U, 7.1 × 10–7
Sv/Bq) (International Commission on
Radiological Protection 1994).
In men, uranium exposure was associated
with elevated CTx levels (Figure 2) with the
p-values in the robust regression 0.05 for ura-
nium in water, 0.16 for daily intake, and
0.16 for cumulative intake. The correspond-
ing p-values in conventional linear regression
analyses were 0.01, 0.02, and 0.03. There was
an indication of an association between
increased levels of osteocalcin and uranium
concentrations in drinking water (p = 0.19;
p-value in the conventional linear regression
was 0.04). Levels of P1NP were not associated
with uranium exposure. Uranium concentra-
tions in urine expressed as micrograms per
liter or micrograms per millimole creatinine
were not associated with the markers of bone
turnover.
Increased urinary excretion of calcium
tended to be associated with increased CTx
levels (p-value from the robust regression was
0.10), and some indication was found for
increased urinary excretion of phosphate with
decreased osteocalcin levels (p = 0.16) in men.
The other associations between calcium or
phosphate excretion and bone turnover were
not close to the statistical significance in the
robust regression.
In women, uranium exposure was not asso-
ciated with any indicators of bone turnover
(Figure 2). Urinary excretion of neither cal-
cium nor phosphate was associated with bone
markers.
Those 32 study persons who reported a
history of any bone fractures in adulthood were
not statistically significantly more exposed
to uranium than those without such history
(median cumulative doses of uranium of
124 mg in those with fractures vs. 117 mg in
those without). There were no differences in
the levels of the markers of bone metabolism
among those with or without past fractures
(data not shown).
Discussion
The uranium exposure covered a wide range
of concentrations in this study. More than half
of the study persons used drinking water with
uranium concentration exceeding 15 µg/L,
which is the new provisional World Health
Organization (WHO) guideline value for ura-
nium in drinking water (WHO 2004).
In men, chronic uranium exposure indi-
cated by uranium level in drinking water as well
as daily and cumulative uranium intakes tended
to be associated with the increased levels of the
bone resorption marker CTx and to a lesser
degree of the bone formation marker osteocal-
cin. The association of uranium exposure and
CTx reached a marginal signiﬁcance at the 5%
level in the robust analysis that down-weights
the inﬂuence of possible outliers and was signiﬁ-
cant in the conventional regression analysis.
This ﬁnding may indicate that bone is a possible
target of chemical toxicity of natural uranium.
In contrast to men, no statistically signiﬁ-
cant associations with uranium exposure and
the measured bone turnover markers were
observed in women. In women, subtle effects
may be masked by other strong determinants
of bone turnover, such as menopause and
hormone use. Potential confounding factors
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Table 3. Correlation matrix for the log-transformed uranium (Ln U) exposure variables.
Ln U in water Ln U intake Ln U cumulative Ln U in
(µg/L) (µg/day) intake (g) urine (µg/L)
Ln U in water (µg/L) 1
Ln U intake (µg/day) 0.98 1
Ln U cumulative intake (g) 0.93 0.95 1
Ln U in urine (µg/L) 0.89 0.89 0.84 1
Ln U in urine (µg/mmol creatinine) 0.86 0.88 0.84 0.96
Table 4. R2 and p-values for the robust regression
models of men and women including uranium con-
centration in water adjusted for age and smoking
and estrogen use (for women).
Men Women
Outcome R2 p-Value R2 p-Value
Osteocalcin 0.21 < 0.001 0.10 0.02
P1NP 0.13 < 0.001 0.12 0.008
CTx 0.14 < 0.001 0.12 0.00Article | Uranium in drinking water and bone
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including menopausal status, recent body
weight changes, physical activity, and calcium
and vitamin D supplementation could not be
effectively controlled in the present study,
although they all have an influence on bone
metabolism (Delmas 2000; Watts 1999).
The subtle effects of uranium on bone
markers in men could be explained by different
mechanisms. Accumulation of uranium in
bone may have a local effect on bone metabo-
lism or structure. Direct effect of uranium on
bone has been shown in animal studies, with
accumulation of uranium into bone (Leggett
and Pellmar 2003; Pellmar et al. 1999). In lab-
oratory animals exposure has been shown to
modify bone formation and resorption (Diaz
Sylvester et al. 2002; Guglielmotti et al. 1984;
Ubios et al. 1991). Direct bone effect is also
supported by the present observation that the
change in bone markers was more strongly
associated with uranium concentration in
drinking water and daily or cumulative intake
than with uranium concentration in urine.
Concentration in water and intake likely
describe long-term exposure to uranium and
consequently accumulation to bone better than
concentration in urine, which reflects recent
exposure.
Uranium might have an effect on bone
also via its inﬂuence on kidneys. Chronic renal
insufﬁciency has been reported to affect bone
metabolism (Malluche 1995; Malluche and
Faugere 1990). On the other hand, elevated
levels of bone markers have been observed in
patients with kidney damage due to chronic
exposure to cadmium, another metal toxic to
the kidney (Aoshima et al. 2003; Kido et al.
1990). Cadmium-induced osteoporosis is
associated specifically with tubular damage,
including increased excretion of calcium in
urine (Jin et al. 2004). However, uranium in
drinking water does not cause severe kidney
damage or cytotoxicity even at high exposure
levels (Kurttio et al. 2002; Zamora et al.
1998), nor had the subjects in the present
study significant kidney insufficiency. We
have earlier shown that intake of natural ura-
nium in drinking water is associated with
increased fractional excretion of calcium and
phosphate (Kurttio et al. 2002). By increasing
leakage of calcium into urine by disturbing its
tubular reabsorption, uranium exposure could
secondarily lead to bone resorption. However,
the increased excretion of calcium and phos-
phate in urine has been suggested to be associ-
ated most strongly with the recent uranium
exposure (uranium in urine) (Kurttio et al.
2002), and in the present study CTx was asso-
ciated with long-term exposure to uranium
(concentration in water, and daily and cumu-
lative intake). Accordingly, on the basis of ear-
lier animal studies and the present results, we
propose that the relationship between ura-
nium intake and bone markers reflects the
direct effect of uranium on bone.
Only uranium was analyzed from the water
samples. It is possible that other elements or
constituents in drinking water confound the
results. To be a confounding factor, it should
be associated with both uranium concentration
and the outcome measures. However, other
heavy metals, including cadmium and lead,
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Figure 1. Background levels of the markers of bone turnover in men (A–C) and women (D–F). The lines repre-
sent the estimates from the robust regression models described in the text. In A–C, curvature lines and p-values
represent the estimates of squared age variable. All p-values for associations between the linear age vari-
able and all outcome variables were < 0.01. In D–F, open circles represent women who do not use estrogen,
and shaded circles, women who use estrogen. Error bars are 95% confidence intervals of age groups.
p-Values are given for the of 55–65-year age group compared with the < 45-year age group and for the estro-
gen users compared with nonusers (estro): (A) p = 0.06; (B) p = 0.13; (C) p = 0.03; (D) p = 0.08 (55–65 years),
p = 0.005 (estro); (E) p = 0.09 (55–65 years), p < 0.001 (estro); (F) p = 0.07 (55–65 years), p = 0.001 (estro).
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Figure 2. Associations between biochemical markers of bone turnover and uranium (U) exposure expressed
as concentration in drinking water or as daily intake in men (A–F) and women (G–I). Regression lines and
p-values were taken from the robust regression models. (A) p = 0.19; (B) p = 0.46; (C) p = 0.05; (D) p = 0.23;
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occur extremely rarely in substantial concen-
trations in Finnish drilled wells and are not
correlated with uranium concentrations
(Kurttio et al., unpublished data). Therefore,
other elements in drinking water are very
unlikely to confound the results.
In this study population, drinking water is
expected to be the predominant source of ura-
nium, especially among those with elevated ura-
nium concentrations in well water. The study
persons had used drinking water from the
drilled wells with measured uranium concentra-
tions for at least 1 year. Therefore, a steady state
uranium exposure can be anticipated.
Uranium concentration in the private wells
drilled in bedrock may vary considerably over
time, and therefore a spot sampling may not
accurately represent the long-term uranium
exposure. Additionally, the daily and cumula-
tive intakes of uranium are based on study per-
sons’ own estimates on their drinking water
consumption, which also adds uncertainty.
Although urinary uranium concentration is
unaffected by these sources of uncertainty, it is
limited mainly to current uranium exposure.
Yet there is a high correlation between ura-
nium exposure indicators.
Substantial variation in age complicates the
interpretation of the results because several
age-dependent factors influencing the bone
turnover may mask possible effects of uranium.
As was seen in this study, the levels of bone
turnover markers remain approximately stable
from 25 years of age to menopausal age
(~ 55 years) in women and to 65 years of age in
men. Obviously focusing on limited ages would
facilitate the interpretation of the results.
Conclusions
We found some evidence for an association
between increased bone turnover and exposure
to natural uranium through drinking water
among men. The fact that similar effects were
not observed in women may be due to other
stronger factors in bone metabolism of women
that may mask the effects of uranium. This
study suggests that in addition to kidneys, bone
may be another target for uranium toxicity.
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